New Scientist covered Model Medicines’ MDL-001 as a potential multipurpose antiviral pill designed to address a wide range of viral infections, including colds, norovirus, flu, and COVID-19. The article highlights how AI helped identify a previously overlooked drug candidate with potential broad-spectrum antiviral activity, with subsequent animal testing suggesting the prediction may be directionally promising. The feature positions MDL-001 as an example of Model Medicines’ AI-driven approach to drug discovery, using its GALILEO™ AI platform to identify and advance therapeutic candidates for areas of significant unmet need.